Skip to main content
SpringerLink
Log in

Coinfection with Hepatitis B or C in People Living with HIV Undergoing Immunosuppressive Therapy

  • Chapter
  • First Online:
HIV-associated Hematological Malignancies

  • 601 Accesses

Abstract

HIV and both the hepatitis B virus (HBV) and hepatitis C virus (HCV) share similar forms of transmission (unprotected sexual intercourse, injection drug use (IDU), and transfusion of blood products), which explains why coinfection with HIV and either HBV, HCV, or even both is not uncommon. Additionally, patients coinfected with HIV and hepatitis B or C are at a higher risk of decompensation of liver disease and development of cirrhosis [1–5]. Therefore, screening of all patients diagnosed with HIV for hepatitis infection is critical to identify coinfection and prevent excess morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Deng LP, Gui XE, Zhang YX, et al. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2009;15:996–1003.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.

    Article  CAS  PubMed  Google Scholar 

  3. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800–5.

    Article  CAS  PubMed  Google Scholar 

  4. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593–601.

    Article  PubMed  Google Scholar 

  5. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48:1763–71.

    Article  PubMed  Google Scholar 

  6. Price H, Bansi L, Sabin CA, et al. Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. PLoS One. 2012;7:e49314.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Pittman C, Plitt S, Birse T, et al. Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta. Can J Infect Dis Med Microbiol. 2014;25:e8–13.

    PubMed Central  PubMed  Google Scholar 

  8. Spradling PR, Richardson JT, Buchacz K, et al. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepat. 2010;17:879–86.

    Article  CAS  PubMed  Google Scholar 

  9. Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.

    Article  CAS  PubMed  Google Scholar 

  10. Coffin CS, Mulrooney-Cousins PM, Osiowy C, et al. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol. 2014;60:347–53.

    Article  PubMed  Google Scholar 

  11. Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, et al. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: a review of prevalence, diagnosis and clinical significance. World J Hepatol. 2015;7:253–60.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Chadwick D, Doyle T, Ellis S, et al. Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: a point prevalence study. HIV Med. 2014;15:189–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Petty LA, Steinbeck JL, Pursell K, et al. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin N Am. 2014;28:477–99.

    Article  Google Scholar 

  14. Marcellin F, Lorente N, Demoulin B, et al. Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sex Transm Infect. 2015;91:21–3.

    Article  PubMed  Google Scholar 

  15. Kouyos RD, Rauch A, Braun DL, et al. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis. 2014;210:1555–61.

    Article  PubMed  Google Scholar 

  16. Akselrod H, Grau LE, Barbour R, et al. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. Am J Public Health. 2014;104:1713–21.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Sanchez MA, Scheer S, Shallow S, et al. Epidemiology of the viral hepatitis-HIV syndemic in San Francisco: a collaborative surveillance approach. Public Health Rep. 2014;129 Suppl 1:95–101.

    PubMed Central  PubMed  Google Scholar 

  18. Serrano-Villar S, Sobrino-Vegas P, Monge S, et al. Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. J Viral Hepat. 2015;22:496–503.

    Article  CAS  PubMed  Google Scholar 

  19. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–44.e3.

    Article  PubMed  Google Scholar 

  20. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.

    Article  CAS  PubMed  Google Scholar 

  21. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–43.

    Article  CAS  PubMed  Google Scholar 

  22. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270–5.

    Article  CAS  PubMed  Google Scholar 

  24. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521–30.

    Article  PubMed  Google Scholar 

  25. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55–9.

    Article  CAS  PubMed  Google Scholar 

  26. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703–11.

    Article  PubMed  Google Scholar 

  27. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320–5.

    Article  CAS  PubMed  Google Scholar 

  29. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.

    Article  CAS  PubMed  Google Scholar 

  30. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.

    Article  CAS  PubMed  Google Scholar 

  31. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–8.

    Article  CAS  PubMed  Google Scholar 

  32. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.

    Article  CAS  PubMed  Google Scholar 

  33. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med. 2003;348:177–8.

    Article  CAS  PubMed  Google Scholar 

  34. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185–92.

    Article  CAS  PubMed  Google Scholar 

  35. Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther. 2010;15:963–74.

    Article  CAS  PubMed  Google Scholar 

  36. Martin-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9.

    Article  PubMed  Google Scholar 

  37. Wilkins E, Nelson M, Agarwal K, et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013;14 Suppl 4:1–71.

    CAS  Google Scholar 

  38. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

    Article  PubMed  Google Scholar 

  39. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–9; quiz e16–7.

    Article  CAS  PubMed  Google Scholar 

  40. Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.

    Article  PubMed  Google Scholar 

  41. Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999;46:2925–30.

    CAS  PubMed  Google Scholar 

  42. Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol. 2001;67:45–50.

    Article  CAS  PubMed  Google Scholar 

  43. Faggioli P, De Paschale M, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica. 1997;82:38–42.

    CAS  PubMed  Google Scholar 

  44. Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005;74:158–65.

    Article  PubMed  Google Scholar 

  45. Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83:1224–30.

    Article  CAS  PubMed  Google Scholar 

  46. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.

    Article  CAS  PubMed  Google Scholar 

  47. Zaky AH, Bakry R, El-Sayed MI, et al. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology. 2014;19:412–6.

    Article  PubMed  Google Scholar 

  48. Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99:489–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006;17:1434–40.

    Article  CAS  PubMed  Google Scholar 

  50. Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116:5119–25.

    Article  CAS  PubMed  Google Scholar 

  51. Sridharan A, Curtis SA, Kaner JD, et al. Hepatitis C co-infection in HIV-positive patients treated for lymphoma. ASCO Meet Abstr. 2014;32:8578.

    Google Scholar 

  52. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus–positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte Programs. J Clin Oncol. 2006;24:953–60.

    Article  PubMed  Google Scholar 

  53. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–95.

    Article  Google Scholar 

  54. Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2014;39:1363–75.

    Article  CAS  PubMed  Google Scholar 

  55. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014. Copyright (c) World Health Organization 2014.

    Google Scholar 

  56. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–31.

    Article  CAS  PubMed  Google Scholar 

  57. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232–9.

    Article  CAS  PubMed  Google Scholar 

  58. Graham CS. Hepatitis C and HIV: closing the gaps. JAMA. 2015;313:1217–8.

    Google Scholar 

  59. Hull M, Klein M, Shafran S, et al. CIHR Canadian HIV trials network coinfection and concurrent diseases core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol. 2013;24:217–38.

    PubMed Central  PubMed  Google Scholar 

  60. European AIDS Clinical Society (EACS) guidelines. 22 Apr 2015. http://www.eacsociety.org/files/guidelines-7.1-english.pdf.

  61. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 22 Apr 2015. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.

  62. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94.

    Article  CAS  PubMed  Google Scholar 

  64. Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18:1711–6.

    Article  CAS  PubMed  Google Scholar 

  65. Gisbert JP, Garcia-Buey L, Pajares JM, et al. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther. 2005;21:653–62.

    Article  CAS  PubMed  Google Scholar 

  66. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468–73.

    Article  CAS  PubMed  Google Scholar 

  67. La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49:557–63.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

I would like to thank Dr. Minhhuyen T. Nguyen for critically reviewing this chapter.

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Temple BMT Program, Temple University Health System, Philadelphia, PA, USA

    Stefan K. Barta MD, MS, MRCP (UK)

Authors
  1. Stefan K. Barta MD, MS, MRCP (UK)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan K. Barta MD, MS, MRCP (UK) .

Editor information

Editors and Affiliations

  1. Department of Hematology and Oncology, Red Cross Hospital, Uni of Munich, Munich, Germany

    Marcus Hentrich

  2. Dept. of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Stefan K. Barta

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Barta, S.K. (2016). Coinfection with Hepatitis B or C in People Living with HIV Undergoing Immunosuppressive Therapy. In: Hentrich, M., Barta, S. (eds) HIV-associated Hematological Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-26857-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26857-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26855-2

  • Online ISBN: 978-3-319-26857-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation